LONDON, UK / ACCESSWIRE / January 23, 2018 / Active-Investors.com has just released a free research report on NuCana PLC (NASDAQ: NCNA). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=NCNA as the Company's latest news hit the wire. On January 19, 2018, the Company announced interim results from the ABC-08 Study, a Phase-1b clinical trial evaluating Acelarin® in combination with cisplatin, as a first-line treatment for advanced biliary tract cancer. The results were presented at the 2018 ASCO Gastrointestinal Cancer Symposium (ASCO GI) in San Francisco, California. Register today and get access to over 1,000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, NuCana most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/?symbol=NCNA
ABC-08 Study to Establish the Optimal Dose of Acelarin® in Combination with Cisplatin
ABC-08 Study is a Phase-1b, multi-center, open-label study to assess the combination of a first-in-class NUC-1031 with cisplatin, and also to establish the optimal combination of both in patients with advanced biliary tract cancer. Eight patients with advanced biliary tract cancer received Acelarin® (625mg/m2) and cisplatin (25mg/m2) on days one and eight of a three-week cycle.
Patients showed a disease control rate of 63%, including one complete responder, three partial responders and one with stable disease. Additionally, the one patient with Stable Disease, whose cancer initially had been considered unsuitable for surgical resection, went on to have surgery to remove the tumor completely. No unexpected adverse events were observed. Acelarin® at 625mg/m2 with cisplatin at 25mg/m2 was determined to be the optimal combination.
NuCana Plans to Initiate a Phase-3 Study of Acelarin® and Cisplatin in Front-Line Advanced Biliary Tract Cancer
Hugh S. Griffith, Chief Executive Officer of NuCana, mentioned that the Company is encouraged by the exceptional results achieved so early in this study. Consistent with the NuCana's strategy of rapidly advancing its new medicines in multiple cancer types, and based on the results of this study, the Company plans to initiate a pivotal study of Acelarin® and cisplatin in front-line advanced biliary tract cancer in 2018.
NuCana Announced Patients Enrolment in Phase-2 Study of Acelarin® in Platinum-Resistant Ovarian Cancer
In November 2017, NuCana announced the enrollment of the first patients in both the United States and the United Kingdom in its PRO-105 study evaluating single-agent Acelarin in patients with platinum-resistant ovarian cancer. The PRO-105 study will enroll up to 64 patients with platinum-resistant ovarian cancer who have relapsed following three or more prior lines of chemotherapy. In September 2017, the Company presented data from Phase-1b trial of its Acelarin® at ESMO 2017. Results from the trial showed that Acelarin®, when combined with carboplatin, was well tolerated and demonstrated clinical activity in women with recurrent platinum-resistant and platinum-sensitive ovarian cancer.
About Biliary Tract Cancer
Biliary tract cancers are invasive carcinomas that arise from the epithelial lining of the gallbladder and bile ducts. These include intrahepatic, perihilar, and distal biliary tree cancers as well as carcinoma arising from the gallbladder. Biliary obstruction is the most common cause of symptoms and is associated with pruritis, abdominal pain, light colored stools, and dark urine. Complete surgical resection offers the only chance for cure for this cancer, however only 10% of patients present with early-stage disease and are considered surgical candidates.
About Acelarin® (NUC-1031)
Acelarin®, NuCana's lead product candidate was designed to overcome the key cancer resistance mechanisms associated with the nucleoside analog, gemcitabine, and has been evaluated in over 130 patients with cancer. The Company believes that Acelarin® could replace gemcitabine in certain cancer indications and have utility across a range of other cancers.
About NuCana PLC
Founded in 1997, NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying its phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines. The Company is headquartered in Edinburgh, United Kingdom.
Stock Performance Snapshot
January 22, 2018 - At Monday's closing bell, NuCana's stock rose 6.29%, ending the trading session at $21.80.
Volume traded for the day: 527.99 thousand shares, which was above the 3-month average volume of 71.17 thousand shares.
Stock performance in the last month – up 102.79%; previous three-month period – up 51.60%; and year-to-date - up 115.63%
After yesterday's close, NuCana's market cap was at $489.85 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.9% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visithttp://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
